Clinical Trials Logo

Abortion, Habitual clinical trials

View clinical trials related to Abortion, Habitual.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06249230 Not yet recruiting - Clinical trials for Recurrent Miscarriage

The Analysis of Risk Factors for Recurrent Pregnancy Loss and Prediction of Pregnancy Loss Risk

Start date: January 31, 2024
Phase:
Study type: Observational

Based on the comprehensive etiological screening results of patients with recurrent pregnancy loss, including basic characteristics, coagulation function indicators, autoimmune indicators, endocrine indicators, and gynecological ultrasound examination results, as well as the outcome of subsequent pregnancy after the patient's visit, analyze the independent risk factors affecting recurrent pregnancy loss, construct and validate an abortion risk prediction model to predict the risk of subsequent pregnancy loss in patients with recurrent pregnancy loss, and classify the patient's risk, Screening high-risk populations and guiding clinical early intervention and active treatment to improve pregnancy success rates.

NCT ID: NCT06182878 Not yet recruiting - Clinical trials for Recurrent Pregnancy Loss

Tender Loving Care for Recurrent Pregnancy Loss

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The goal of this investigational study is to evaluate participation in a weekly, interactive, tender loving care messaging platform impact on pregnancy outcomes in patients with recurrent pregnancy loss. The main questions it aims to answer are: (1) does participation in weekly, interactive tender loving care messages increase live birth rates in patients with recurrent pregnancy loss? (2) Does participation in weekly, interactive tender loving care messages increase patients' quality of life? Does participation in weekly, interactive tender loving care messages decrease patients' depressive symptoms? Participants will be asked to interact with weekly messages providing prenatal counseling and support. Additionally, patients will be asked to complete the fertility quality of life survey several times over the course of the pregnancy.

NCT ID: NCT06164015 Not yet recruiting - Clinical trials for Recurrent Miscarriage

3D Ultrasound to Assess in Recurrent Miscarriage

3D-ARM
Start date: December 1, 2023
Phase:
Study type: Observational

This observational study aims to compare the prevalence of acquired abnormalities of the uterus (fibroids, polyps, intrauterine adhesions, adenomyosis) in women who have recurrent miscarriages with the fertile population.

NCT ID: NCT06163092 Not yet recruiting - Clinical trials for Recurrent Miscarriage

Chronic Endometritis and Benefits of Antibiotics in Women With Recurrent Miscarriage

Start date: April 1, 2024
Phase:
Study type: Observational

The aim of the study is to estimate the incidence of CE, evaluate the endometrial microorganism of CE, and investigate the therapeutic benefits of antibiotics for women with unexplained recurrent miscarriage and CE.

NCT ID: NCT05658445 Not yet recruiting - Abortion, Habitual Clinical Trials

Potential Role of microRNA 410 and BIRC7 Pathways in Unexplained Recurrent Spontaneous Miscarriage

microRNA410
Start date: January 1, 2023
Phase:
Study type: Observational [Patient Registry]

The definition of recurrent spontaneous abortion (RSA) has changed over the years, and most societies now advocate defining RSA as two or three consecutive or discontinuous miscarriages with the same sexual partner before 24 weeks gestation In recent years, the incidence of this disease has been on the rise, occurring in about 1%- 5% of pregnancy in women at childbearing age, and the success rate of second pregnancy in RSA females has been significantly reduced The etiology of RSA is extremely complex, including anatomical factors, genetic factors, endocrine factors, infectious and immune factors, and pre-thrombosis etiology. However, the cause of the disease is unclear in half of patients and known as unexplained recurrent spontaneous abortion (URSA)

NCT ID: NCT05612620 Not yet recruiting - Microbiome Clinical Trials

Elucidating the Microbiome in Patients With Recurrent Pregnancy Loss

Start date: November 14, 2022
Phase:
Study type: Observational [Patient Registry]

Recurrent pregnancy loss (RPL) is defined as 2 or more consecutive miscarriages1 This condition affects about 1-3% of couples during their reproductive years. The role of vaginal infections in RPL is controversial and microbiological screening is not recommended as per the international guidelines. Current theories suggest that altered vaginal and uterine microbiota may trigger an inflammatory response in the endometrium even without the presence of clinical infection which could affect the success of embryo implantation and future development of pregnancy2 .Changes in the uterine microbiota can lead to chronic endometritis (CE). This condition is caused by continuing inflammation of the endometrium, involving a variety of common bacterial and yeast species and has been associated with RPL3 . Notably, CE can be found in up to 45% of infertile patients4. Current diagnosis of CE is based on histopathological examination, immunohistochemistry assay for CD138 cells and morphological appearance on hysteroscopy. While antibiotic treatment can improve ongoing pregnancy rates in patients with RPL treatment success is still partial and unpredictable. A mechanistic link is yet to be established between vaginal and uterine microbiota and RPL and it is unknown whether restoration of the microbiome in patients with RPL can improve pregnancy outcomes.

NCT ID: NCT05557201 Not yet recruiting - Miscarriage Clinical Trials

Cohort of Patients Presenting Unexplained Recurrent Miscarriages and Identification of Early Miscarriage Recidivism Factors

FALCO
Start date: October 2022
Phase:
Study type: Observational

About 1 to 3% of women of childbearing age have repeated early spontaneous miscarriages (RCF) defined by at least 3 fetal losses before 14 weeks of gestation. RCFs may be related to parental chromosomal abnormalities, congenital or acquired uterine abnormalities, hormonal causes (e.g. type 1 and 2 diabetes, ovarian failure), infectious etiology, constitutional or acquired thrombophilia or sickle cell disease. The presence of antiphospholipid antibodies, antithyroid and anti-transglutaminase antibodies in approximately 10% of cases suggests an autoimmune origin for these fetal losses. The role of other antibodies, in particular unconventional antiphospholipid antibodies, remains to be established. Indeed half of RCF cases would be due to an immunological dysregulation of the mother leading to a decrease in tolerance to the fetus. Several studies have shown immune abnormalities, such as an imbalance of pro and anti-inflammatory cytokines, an increase in cytotoxic cells and a defect in regulatory cells in the blood of patients. The assessment of these immune abnormalities is not currently carried out routinely in France in women with recurrent early miscarriages. When one of these known causes is excluded, it is unexplained RCF which represents 50% of RCF. In these women with unexplained RCF, slightly more than half could be linked to aneuploidies and primary recurrent spontaneous abortions. The evaluation of the degree of aneuploidy and the genetic origin of fetal losses remains difficult, the examination of the sample of tissue from the miscarriage being rarely available, due to the spontaneous nature of the loss. The constitution of a prospective cohort of patients with RCF is an essential step in exploring the factors associated with the success of treatment.

NCT ID: NCT05520112 Not yet recruiting - Clinical trials for Recurrent Pregnancy Loss

Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells

Start date: November 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of Recurrent pregnancy loss using mesenchymal stem cells capable of differentiation in the endometrial-decidual direction.

NCT ID: NCT05510622 Not yet recruiting - Vaginal Microbiome Clinical Trials

Uterine Microbiome in Recurrent Pregnancy Loss

Start date: August 20, 2022
Phase:
Study type: Observational

The female genital tract microbiome may reflect female reproductive health and may be related to pregnancy outcomes. Disturbances in this microbiome may be associated with adverse reproductive outcomes. The investigators hypothesize that the endometrial and vaginal microbiome composition in women with a history of recurrent pregnancy loss are different, compared with those in normal fertile women.

NCT ID: NCT05341856 Not yet recruiting - Clinical trials for Recurrent Pregnancy Loss

Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL

Start date: May 1, 2022
Phase: Early Phase 1
Study type: Interventional

compare uterine artery blood flow before and after the administration of Isosorbide mononitrate as a nitric oxide donor during mid secretory phase of menstrual cycle for patients with unexplained recurrent pregnancy loss.